close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

117.85 -0.45 (-0.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant
Via Stocktwits
Discover the top S&P500 movers in Friday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Gilead Sciences (GILD) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Gilead Sciences (NASDAQ:GILD) Beats Q2 Sales Targets
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.8% year on year to $7.08 billion. On the other hand, the... 
Via StockStory
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Gilead Sciences's Earnings Outlook
 
Via Benzinga
Price Over Earnings Overview: Gilead Sciences
 
Via Benzinga
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?
Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling. 
Via Investor's Business Daily
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings
 
Via Benzinga
Arcus (RCUS) Q2 Revenue Jumps 310%
Via The Motley Fool
Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?
U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names. 
Via Benzinga
Topics Government World Trade
Gilead Sciences Inc (NASDAQ:GILD) Meets Caviar Cruise Quality Investing Criteria
The Caviar Cruise strategy identifies high-quality stocks like Gilead Sciences (GILD) for long-term investment, focusing on strong growth, ROIC, low debt, and solid cash flow. GILD excels in... 
Via Chartmill
Topics Economy
Upcoming Earnings Calls This Week: August 4th - August 10th, 2025
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial... 
Via MarketMinute
Topics Artificial Intelligence Economy
Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
Tango (TNGX) Q2 Revenue Drops 52%
Via The Motley Fool
Topics Intellectual Property
GILEAD SCIENCES INC (NASDAQ:GILD) Shows Strong Technical Breakout Potential with High Ratings
Gilead Sciences (GILD) shows strong technical breakout potential with a high Technical Rating (10) and Setup Rating (8), indicating upward momentum and consolidation before a possible breakout. 
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic
pheton-holdings-dismisses-rumors-of-acquisition-by-gilead 
Via Stocktwits
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Chinese Health Care Stock Pheton Holdings Collapses After Short Seller Warns Of Manipulation By 'Overseas Scammers'
 
Via Benzinga
Why Gilead Sciences Stock Slipped Today
Changes in a federal healthcare authority could negatively impact one of the company's important businesses. 
Via The Motley Fool
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive
The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting... 
Via Stocktwits
Visa, Disney, Blackstone And A Health Care Stock On CNBC's 'Final Trades'
Visa, which will report third quarter results on Tuesday, July 29, is analyst Stephanie Link's final trade. 
Via Benzinga
Why Gilead Sciences (GILD) Stock Is Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval... 
Via StockStory
Topics Stocks World Trade
Why Gilead Sciences Stock Just Popped
Gilead stock is flashing "buy" in bright green letters. 
Via The Motley Fool
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates. 
Via Benzinga
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet
Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday. 
Via Stocktwits
Topics Workforce
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today